TY - JOUR
T1 - Association of Kidney Function Measures With Signs of Neurodegeneration and Small Vessel Disease on Brain Magnetic Resonance Imaging
T2 - The Atherosclerosis Risk in Communities (ARIC) Study
AU - Scheppach, Johannes B.
AU - Wu, Aozhou
AU - Gottesman, Rebecca F.
AU - Mosley, Thomas H.
AU - Arsiwala-Scheppach, Lubaina T.
AU - Knopman, David S.
AU - Grams, Morgan E.
AU - Sharrett, A. Richey
AU - Coresh, Josef
AU - Koton, Silvia
N1 - Publisher Copyright:
© 2022 National Kidney Foundation, Inc.
PY - 2023/3
Y1 - 2023/3
N2 - Rationale & Objective: Chronic kidney disease (CKD) is a risk factor for cognitive decline, but evidence is limited on its etiology and morphological manifestation in the brain. We evaluated the association of estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) with structural brain abnormalities visible on magnetic resonance imaging (MRI). We also assessed whether this association was altered when different filtration markers were used to estimate GFR. Study Design: Cross-sectional study nested in a cohort study. Setting & Participants: 1,527 participants in the Atherosclerosis Risk in Communities (ARIC) Study. Predictors: Log(UACR) and eGFR based on cystatin C, creatinine, cystatin C and creatinine in combination, or β2-microglobulin (B2M). Outcomes: Brain volume reduction, infarcts, microhemorrhages, white matter lesions. Analytical Approach: Multivariable linear and logistic regression models fit separately for each predictor based on a 1-IQR difference in the predictor value. Results: Each 1-IQR lower eGFR was associated with reduced cortex volume (regression coefficient: −0.07 [95% CI, −0.12 to −0.02]), greater white matter hyperintensity volume (logarithmically transformed; regression coefficient: 0.07 [95% CI, 0.01-0.15]), and lower white matter fractional anisotropy (regression coefficient: −0.08 [95% CI, −0.17 to −0.01]). The results were similar when eGFR was estimated with different equations based on cystatin C, creatinine, a combination of cystatin C and creatinine, or B2M. Higher log(UACR) was similarly associated with these outcomes as well as brain infarcts and microhemorrhages (odds ratios per 1-IQR-fold greater UACR of 1.31 [95% CI, 1.13-1.52] and 1.30 [95% CI, 1.12-1.51], respectively). The degree to which brain volume was lower in regions usually susceptible to Alzheimer disease and LATE (limbic-predominant age-related TDP-43 [Tar DNA binding protein 43] encephalopathy) was similar to that seen in the rest of the cortex. Limitations: No inference about longitudinal effects due to cross-sectional design. Conclusions: We found eGFR and UACR are associated with structural brain damage across different domains of etiology, and eGFR- and UACR-related brain atrophy is not selective for regions typically affected by Alzheimer disease and LATE. Hence, Alzheimer disease or LATE may not be leading contributors to neurodegeneration associated with CKD.
AB - Rationale & Objective: Chronic kidney disease (CKD) is a risk factor for cognitive decline, but evidence is limited on its etiology and morphological manifestation in the brain. We evaluated the association of estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) with structural brain abnormalities visible on magnetic resonance imaging (MRI). We also assessed whether this association was altered when different filtration markers were used to estimate GFR. Study Design: Cross-sectional study nested in a cohort study. Setting & Participants: 1,527 participants in the Atherosclerosis Risk in Communities (ARIC) Study. Predictors: Log(UACR) and eGFR based on cystatin C, creatinine, cystatin C and creatinine in combination, or β2-microglobulin (B2M). Outcomes: Brain volume reduction, infarcts, microhemorrhages, white matter lesions. Analytical Approach: Multivariable linear and logistic regression models fit separately for each predictor based on a 1-IQR difference in the predictor value. Results: Each 1-IQR lower eGFR was associated with reduced cortex volume (regression coefficient: −0.07 [95% CI, −0.12 to −0.02]), greater white matter hyperintensity volume (logarithmically transformed; regression coefficient: 0.07 [95% CI, 0.01-0.15]), and lower white matter fractional anisotropy (regression coefficient: −0.08 [95% CI, −0.17 to −0.01]). The results were similar when eGFR was estimated with different equations based on cystatin C, creatinine, a combination of cystatin C and creatinine, or B2M. Higher log(UACR) was similarly associated with these outcomes as well as brain infarcts and microhemorrhages (odds ratios per 1-IQR-fold greater UACR of 1.31 [95% CI, 1.13-1.52] and 1.30 [95% CI, 1.12-1.51], respectively). The degree to which brain volume was lower in regions usually susceptible to Alzheimer disease and LATE (limbic-predominant age-related TDP-43 [Tar DNA binding protein 43] encephalopathy) was similar to that seen in the rest of the cortex. Limitations: No inference about longitudinal effects due to cross-sectional design. Conclusions: We found eGFR and UACR are associated with structural brain damage across different domains of etiology, and eGFR- and UACR-related brain atrophy is not selective for regions typically affected by Alzheimer disease and LATE. Hence, Alzheimer disease or LATE may not be leading contributors to neurodegeneration associated with CKD.
KW - Albuminuria
KW - Atherosclerosis Risk in Communities (ARIC) Study
KW - brain infarcts
KW - cerebral small vessel disease
KW - chronic kidney disease (CKD)
KW - creatinine
KW - cystatin C
KW - diffusion tensor imaging
KW - estimated glomerular filtration rate (eGFR)
KW - magnetic resonance imaging (MRI)
KW - microhemorrhages
KW - neurodegeneration
KW - urinary albumin-creatinine ratio (UACR)
KW - white matter lesions
KW - β-microglobulin (B2M)
UR - http://www.scopus.com/inward/record.url?scp=85142691001&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2022.07.013
DO - 10.1053/j.ajkd.2022.07.013
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36179945
AN - SCOPUS:85142691001
SN - 0272-6386
VL - 81
SP - 261-269.e1
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -